J. Cochran

发表

Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity

R. Kimura, A. M. Levin, F. V. Cochran, 2009, Proteins.

Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library

H. Steven Wiley, Jennifer R. Cochran, James R. Coleman, 2003, Nature Biotechnology.

4.14 Rational and Combinatorial Methods to Create Designer Protein Interfaces

S. Park, J. Cochran, B. H. Lui, 2017 .

4.412 – Rational and Combinatorial Methods to Create Designer Protein Interfaces

J. Cochran, B. H. Lui, 2011 .

Interpenetrating polymer network hydrogel scaffolds for artificial cornea periphery

Jennifer R. Cochran, Curtis W. Frank, Luo Luo Zheng, 2015, Journal of Materials Science: Materials in Medicine.

A novel protein‐engineered hepatocyte growth factor analog released via a shear‐thinning injectable hydrogel enhances post‐infarction ventricular function

Lei Cai, Aaron C Mitchell, Jennifer R Cochran, 2017, Biotechnology and bioengineering.

Dual display of proteins on the yeast cell surface simplifies quantification of binding interactions and enzymatic bioconjugation reactions.

J. Cochran, Maria V. Filsinger Interrante, Sungwon Lim, 2017, Biotechnology journal.

Bioactive interpenetrating polymer network hydrogels that support corneal epithelial wound healing.

J. Noolandi, J. Cochran, W. Koh, 2009, Journal of biomedical materials research. Part A.

CD52 Is Elevated on B cells of SLE Patients and Regulates B Cell Function

W. Robinson, J. Cochran, Kartik Bhamidipati, 2021, Frontiers in Immunology.

Phage display and molecular imaging: expanding fields of vision in living subjects

F. V. Cochran, J. Cochran, 2010, Biotechnology & genetic engineering reviews.

Heterochiral Knottin Protein: Folding and Solution Structure.

F. V. Cochran, J. Cochran, Hongtao Yu, 2017, Biochemistry.

Receptor clustering and transmembrane signaling in T cells.

J. Cochran, D. Aivazian, L. Stern, 2001, Trends in biochemical sciences.

TCR: losing its inhibitions?

J. Cochran, J. Stone, L. Stern, 2001, Trends in immunology.

Receptor Proximity, Not Intermolecular Orientation, Is Critical for Triggering T-cell Activation*

J. Cochran, J. Stone, L. Stern, 2001, The Journal of Biological Chemistry.

A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions.

J. Cochran, L. Stern, Jennifer R. Cochran, 2000, Chemistry & biology.

Cutting Edge: Detection of Antigen-Specific CD4+ T Cells by HLA-DR1 Oligomers Is Dependent on the T Cell Activation State1

R. Sékaly, J. Cochran, B. Yassine-Diab, 2001, The Journal of Immunology.

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

Webster K. Cavenee, Edouard C. Nice, Lloyd J. Old, 2009, Proceedings of the National Academy of Sciences.

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

J. Cochran, J. Spicer, L. Whilding, 2017, Oncoimmunology.

Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.

Raymond M. Wang, A. DeMaria, O. L. Kwan, 2015, Biomaterials.

Biocompatibility of poly(ethylene glycol) and poly(acrylic acid) interpenetrating network hydrogel by intrastromal implantation in rabbit cornea.

R. Dalal, J. Noolandi, J. Cochran, 2015, Journal of biomedical materials research. Part A.

Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand

Po-Ssu Huang, J. Cochran, W. Bae, 2020, Proceedings of the National Academy of Sciences.

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors

Howard Y. Chang, Ansuman T. Satpathy, Louai Labanieh, 2022, Cell.

Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors

Louai Labanieh, Ovijit Chaudhuri, J. Cochran, 2021, bioRxiv.

Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication

Rachel E. Brewer, I. Weissman, P. Sorensen, 2021, bioRxiv.

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Rachel E. Brewer, I. Weissman, M. Monje, 2022, Nature Medicine.

Soluble peptide–MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules

Jianzhu Chen, J. Cochran, Q. Ge, 2002, Proceedings of the National Academy of Sciences of the United States of America.

In Vivo Site-Specific Protein Tagging with Diverse Amines Using an Engineered Sortase Variant.

M. Salit, J. Cochran, J. Glasgow, 2016, Journal of the American Chemical Society.

Design and fabrication of an artificial cornea based on a photolithographically patterned hydrogel construct

Fan Zhang, David Myung, Jennifer R Cochran, 2007, Biomedical microdevices.

Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library

J. Cochran, P. Kim, A. E. Powell, 2021, bioRxiv.

Dependent on the T Cell Activation State T Cells by HLA-DR1 Oligomers Is + CD4Cutting Edge: Detection of Antigen-Specific

R. Sékaly, J. Cochran, B. Yassine-Diab, 2000 .

Functional Mutation of Multiple Solvent-Exposed Loops in the Ecballium elaterium Trypsin Inhibitor-II Cystine Knot Miniprotein

R. Kimura, J. Cochran, Zhen Cheng, 2011, PloS one.

Imaging Integrin Expression in Living Subjects Engineered Knottin Peptides : A New Class of Agents for

S. Gambhir, R. Kimura, J. Cochran, 2009 .

Degradable acetalated dextran microparticles for tunable release of an engineered hepatocyte growth factor fragment.

Aaron C Mitchell, J. Cochran, K. Christman, 2016, ACS biomaterials science & engineering.

Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation

C. Bertozzi, J. Cochran, N. Riley, 2020 .

Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro

Lei S. Qi, A. Barron, D. Lewis, 2022, Nature Communications.

Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody library

J. Cochran, P. Kim, A. E. Powell, 2021, Protein science : a publication of the Protein Society.

Measurement of the D*(2010)(+) natural linewidth and the D*(2010)(+)-D-0 mass difference

D. Leith, R. Field, K. Honscheid, 2013 .

Structure and Functional Binding Epitope of V-domain Ig Suppressor of T-cell Activation (VISTA)

Po-Ssu Huang, J. Cochran, I. Mathews, 2019, bioRxiv.

Surface Modification of High-Strength Interpenetrating Network Hydrogels for Biomedical Device Applications

J. Noolandi, J. Cochran, C. Frank, 2013 .

Development of Hydrogel‐Based Keratoprostheses: A Materials Perspective

J. Noolandi, J. Cochran, C. Frank, 2008, Biotechnology progress.

Measurements of translation initiation from all 64 codons in E. coli

Drew Endy, Marc Salit, Lukmaan A. Bawazer, 2016, bioRxiv.

SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness

R. Tibshirani, N. Shah, K. Nadeau, 2020, medRxiv.

Toward the development of an artificial cornea: improved stability of interpenetrating polymer networks.

P. Huie, J. Noolandi, J. Cochran, 2011, Journal of biomedical materials research. Part B, Applied biomaterials.

Engineering growth factors for regenerative medicine applications.

Jeffrey A Hubbell, Aaron C Mitchell, Priscilla S Briquez, 2016, Acta biomaterialia.

Diffusion of Protein through the Human Cornea

J. Noolandi, J. Cochran, C. Frank, 2009, Ophthalmic Research.

The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers.

J. Cochran, L. Stern, L J Stern, 2000, Immunity.

Cystine-knot peptides: emerging tools for cancer imaging and therapy

J. Cochran, J. Bergen, Shelley E. Ackerman, 2014, Expert review of proteomics.

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

C. Bertozzi, J. Cochran, N. Riley, 2021, Nature Chemical Biology.

Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals

Michael Z. Lin, M. Kay, Louai Labanieh, 2020, Nature Methods.

Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.

Aaron C Mitchell, J. Cochran, Spencer C. Alford, 2017, ACS chemical biology.

Applications of Yeast Surface Display for Protein Engineering.

Jennifer R Cochran, J. Cochran, G. M. Cherf, 2015, Methods in molecular biology.

Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics.

J. Cochran, Mihalis S. Kariolis, Shiven Kapur, 2013, Current opinion in biotechnology.

Cell Surface Display Systems For Protein Engineering

F. V. Cochran, J. Cochran, M. Olsen, 2009 .

Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

J. Shrager, S. Vicent, L. Paz-Ares, 2019, Nature Medicine.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

Ryan L. Kelly, D. Lauffenburger, D. Irvine, 2016, Nature Medicine.

Structural basis of the differential binding of engineered knottins to integrins αVβ3 and α5β1

M. Mofrad, M. Arnaout, J. Xiong, 2019, bioRxiv.

Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses

G. Dranoff, R. Hynes, J. Cochran, 2017, The Journal of experimental medicine.

Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma

M. Scott, M. Hayden Gephart, J. Cochran, 2013, Proceedings of the National Academy of Sciences.

Domain-level Antibody Epitope Mapping through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments

J. Cochran, K. Wittrup, Yong-Sung Kim, 2022 .

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

R. Tibshirani, N. Shah, B. Narasimhan, 2020, Science Immunology.

Interrogating and Predicting Tolerated Sequence Diversity in Protein Folds: Application to E. elaterium Trypsin Inhibitor-II Cystine-Knot Miniprotein

Jennifer R. Cochran, Jennifer L. Lahti, Adam P. Silverman, 2009, PLoS Comput. Biol..

Cell-Binding Assays for Determining the Affinity of Protein-Protein Interactions: Technologies and Considerations.

J. Cochran, S. Hunter, 2016, Methods in enzymology.

Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor*

K Dane Wittrup, Gerd Ritter, Nathan E Hall, 2004, Journal of Biological Chemistry.

EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY

Tina N. Davis, Forrest M Kievit, Atique U. Ahmed, 2013 .

Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy

R. Kimura, J. Cochran, Zhen Cheng, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles.

Jennifer R Cochran, J. Cochran, James R Kintzing, 2016, Current opinion in chemical biology.

T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model.

J. Cochran, J. Stone, L. Stern, 2001, Biophysical journal.

High-throughput screening technologies for enzyme engineering.

Jennifer R Cochran, Louai Labanieh, J. Cochran, 2017, Current opinion in biotechnology.

High-throughput analysis and protein engineering using microcapillary arrays

Fanny Sunden, Daniel Herschlag, Bob Chen, 2015, Nature chemical biology.

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies

A. Koong, E. Rankin, A. Giaccia, 2017, The Journal of clinical investigation.

Targeted Contrast-Enhanced Ultrasound Imaging of Tumor Angiogenesis with Contrast Microbubbles Conjugated to Integrin-Binding Knottin Peptides

Sanjiv S. Gambhir, Jennifer R. Cochran, J. Willmann, 2010, Journal of Nuclear Medicine.

Targeting ligand-receptor interactions for development of cancer therapeutics.

J. Cochran, Jun W. Kim, 2017, Current opinion in chemical biology.

Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.

J. Cochran, Maria V. Filsinger Interrante, James R. Kintzing, 2016, Trends in pharmacological sciences.

An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy

T. Hunter, Yu Shi, Louai Labanieh, 2021, Communications Biology.

Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein

Aaron C Mitchell, J. Cochran, R. A. Parra Sperberg, 2018, The Journal of Biological Chemistry.

Engineering High Affinity Protein-Protein Interactions Using a High-Throughput Microcapillary Array Platform.

Bob Chen, Ivan K Dimov, Thomas M Baer, 2017, ACS chemical biology.

A Bioengineered Peptide that Localizes to and Illuminates Medulloblastoma: A New Tool with Potential for Fluorescence-Guided Surgical Resection

J. Cochran, S. Kahn, Christy Wilson, 2014, Cureus.

PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors

S. Gambhir, Louai Labanieh, Amin Aalipour, 2020, Cancer Research.

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.

D. Czerwinski, C. Bertozzi, J. Cochran, 2021, Cell chemical biology.

Engineered ligand‐based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis

Adam P. Silverman, M. Blumenkranz, J. Cochran, 2017, Bioengineering & translational medicine.

Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and αvβ3 integrin

Jennifer L. Lahti, Adam P. Silverman, J. Cochran, 2011, Proceedings of the National Academy of Sciences.

PET Imaging of Integrin Positive Tumors Using 18F Labeled Knottin Peptides

R. Kimura, J. Cochran, Zhen Cheng, 2011, Theranostics.

Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.

Po-Ssu Huang, J. Cochran, I. Mathews, 2019, Cell reports.

An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA

Ryan L. Kelly, Louai Labanieh, J. Cochran, 2020, Scientific Reports.

Multi-phase catheter-injectable hydrogel enables dual-stage protein-engineered cytokine release to mitigate adverse left ventricular remodeling following myocardial infarction in a small animal model and a large animal model.

Alexis J Seymour, Michael J Paulsen, Sam W. Baker, 2020, Cytokine.

Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.

K Dane Wittrup, Jennifer R Cochran, J. Cochran, 2004, Journal of molecular biology.

Measurement of W+W-production in association with one jet in proton-proton collisions at √s = 8 TeV with the ATLAS detector

A. S. Mete, M. P. Casado, P. J. Hsu, 2016 .

Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast

J. Kuriyan, J. Cochran, K. Wittrup, 2005, Proteins.

Developing therapeutic proteins by engineering ligand-receptor interactions.

Adam P. Silverman, Jennifer R Cochran, J. Cochran, 2008, Trends in biotechnology.

eveloping therapeutic proteins by ngineering ligand – receptor nteractions

Adam P. Silverman, J. Cochran, O. S. Jones, 2008 .

Targeted Drug Delivery with an Integrin-Binding Knottin–Fc–MMAF Conjugate Produced by Cell-Free Protein Synthesis

J. Cochran, Maria V. Filsinger Interrante, Alexander R. Steiner, 2016, Molecular Cancer Therapeutics.

Engineering Agatoxin, a Cystine-Knot Peptide from Spider Venom, as a Molecular Probe for In Vivo Tumor Imaging

J. Cochran, Cheuk Lun Leung, Sarah J Moore, 2013, PloS one.

A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects.

S. Gambhir, R. Kimura, J. Cochran, 2010, Bioconjugate chemistry.

Collins Asymmetries in Inclusive Charged KK and Kπ Pairs Produced in e⁺e⁻ Annihilation

D. Leith, R. Field, K. Honscheid, 2015 .

768 Systemic delivery of a tumor-targeted TLR9 agonist conjugate transforms the tumor immune landscape and induces tumor regression in mice

D. Czerwinski, C. Bertozzi, J. Cochran, 2021, Journal for ImmunoTherapy of Cancer.

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

J. Sarkaria, F. White, J. Eckel-Passow, 2021, Neuro-oncology.

Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities.

Jennifer L. Lahti, Adam P. Silverman, A. M. Levin, 2009, Journal of molecular biology.

111In-Labeled Cystine-Knot Peptides Based on the Agouti-Related Protein for Targeting Tumor Angiogenesis

Adam P. Silverman, R. Kimura, J. Cochran, 2012, Journal of biomedicine & biotechnology.

Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation.

J. Cochran, G. Grant, Mark D. Smith, 2016, Angewandte Chemie.

Mutational screens highlight glycosylation as a modulator of colony-stimulating factor 3 receptor (CSF3R) activity

C. Bertozzi, J. Cochran, N. Riley, 2023, The Journal of biological chemistry.

Mutational screens highlight glycosylation as a modulator of CSF3R activity

C. Bertozzi, J. Cochran, Stacy A. Malaker, 2022, bioRxiv.

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.

A. Giaccia, J. Cochran, I. Mathews, 2014, Nature chemical biology.

Targeting of Cancer Cells Using Quantum Dot–Polypeptide Hybrid Assemblies That Function as Molecular Imaging Agents and Carrier Systems

J. Cochran, C. Frank, Stayce E. Beck, 2010, Advanced functional materials.

PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide.

S. Gambhir, D. Felsher, P. Tran, 2010, Cancer research.

Cancer esearch rated Systems and Technologies Imaging of Tumor Neovascularization in a Transgenic R se Model with a Novel 64 Cu-DOTA-Knottin Peptide

S. Gambhir, D. Felsher, P. Tran, 2010 .

Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists

J. Cochran, P. Tsai, Douglas S. Jones, 2011, Proceedings of the National Academy of Sciences.

Elucidation of the interleukin-15 binding site on its alpha receptor by NMR.

K. Garcia, L. Varani, J. Cochran, 2007, Biochemistry.

Identification of N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis and Chemical Design.

Po-Ssu Huang, J. Cochran, R. Sperberg, 2020, ACS chemical biology.

An engineered dimeric fragment of hepatocyte growth factor is a potent c‐MET agonist

J. Cochran, P. Tsai, Cassie Liu, 2014, FEBS letters.

Improved mutants from directed evolution are biased to orthologous substitutions.

Shaun M Lippow, Jennifer R Cochran, Yong-Sung Kim, 2006, Protein engineering, design & selection : PEDS.

A Chemically Cross-Linked Knottin Dimer Binds Integrins with Picomolar Affinity and Inhibits Tumor Cell Migration and Proliferation

F. V. Cochran, J. Cochran, Jun W. Kim, 2014, Journal of the American Chemical Society.

Engineering knottins as novel binding agents.

J. Cochran, Sarah J Moore, 2012, Methods in enzymology.

Cystine‐knot peptides engineered with specificities for αIIbβ3 or αIIbβ3 and αvβ3 integrins are potent inhibitors of platelet aggregation

Adam P. Silverman, J. Cochran, Mihalis S. Kariolis, 2011, Journal of molecular recognition : JMR.

Engineered CD47 protects T cells for enhanced antitumor immunity

I. Weissman, M. Monje, Louai Labanieh, 2023, bioRxiv.

Engineered Proteins Pull Double Duty

Jennifer R. Cochran, J. Cochran, 2010, Science Translational Medicine.

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

G. Raghu, M. Campbell, L. Carter, 2023, bioRxiv.

A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging

F. V. Cochran, J. Cochran, Zhen Cheng, 2013, Amino Acids.

Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin

Adam P. Silverman, S. Gambhir, R. Kimura, 2010, Journal of Nuclear Medicine.

An engineered knottin peptide labeled with 18F for PET imaging of integrin expression.

S. Gambhir, R. Kimura, J. Cochran, 2009, Bioconjugate chemistry.

Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects.

S. Gambhir, R. Kimura, J. Cochran, 2009, Cancer research.

Corrigendum to: “Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface Display” [J. Mol. Biol. (2004) 342, 539–550]

J. Cochran, K. Wittrup, Ginger Chao, 2005 .

Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion

K. Nadeau, J. Zehnder, C. Blish, 2021, Frontiers in Immunology.

Engineering Multivalent and Multispecific Protein Therapeutics

J. Cochran, J. Cochran, Cassie Liu, 2014 .

Knottins: disulfide-bonded therapeutic and diagnostic peptides.

J. Cochran, Cheuk Lun Leung, Sarah J Moore, 2012, Drug discovery today. Technologies.

Engineered epidermal growth factor mutants with faster binding on‐rates correlate with enhanced receptor activation

Jennifer L. Lahti, M. Longaker, J. Cochran, 2011, FEBS letters.

High-throughput analysis and protein engineering using microcapillary arrays

D. Herschlag, I. Dimov, T. Baer, 2015, Nature chemical biology.

An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma

J. Sage, J. Cochran, Griffin G. Hartmann, 2023, Bioengineering & translational medicine.